Cencora, Inc. (NYSE:COR) Stake Lessened by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC lowered its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 4.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,967 shares of the company's stock after selling 1,417 shares during the quarter. Commonwealth Equity Services LLC's holdings in Cencora were worth $7,182,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Swedbank AB boosted its holdings in Cencora by 2.3% in the third quarter. Swedbank AB now owns 1,394,449 shares of the company's stock valued at $313,863,000 after acquiring an additional 31,104 shares during the last quarter. United Bank lifted its stake in shares of Cencora by 4.2% in the 3rd quarter. United Bank now owns 5,601 shares of the company's stock valued at $1,261,000 after purchasing an additional 225 shares in the last quarter. Mutual of America Capital Management LLC grew its holdings in shares of Cencora by 2.9% during the 3rd quarter. Mutual of America Capital Management LLC now owns 21,528 shares of the company's stock worth $4,846,000 after purchasing an additional 605 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in Cencora during the 3rd quarter worth approximately $1,648,000. Finally, Avior Wealth Management LLC lifted its position in Cencora by 66.5% during the third quarter. Avior Wealth Management LLC now owns 6,004 shares of the company's stock valued at $1,351,000 after buying an additional 2,398 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Stock Down 0.0 %

Shares of Cencora stock traded down $0.13 on Monday, hitting $267.30. 1,056,808 shares of the company's stock traded hands, compared to its average volume of 1,377,904. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $277.61. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The stock has a market cap of $51.83 billion, a P/E ratio of 38.02, a PEG ratio of 1.31 and a beta of 0.51. The firm's 50-day moving average is $250.62 and its 200 day moving average is $240.01.

Remove Ads

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.82%. The ex-dividend date was Friday, February 14th. Cencora's dividend payout ratio is currently 31.29%.

Insider Buying and Selling at Cencora

In related news, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares in the company, valued at $3,724,197.76. This represents a 24.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. The trade was a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,970 shares of company stock worth $2,998,670 over the last quarter. 10.80% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently weighed in on COR. Wells Fargo & Company lifted their target price on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a report on Friday, March 14th. Mizuho initiated coverage on Cencora in a research note on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price objective on the stock. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Evercore ISI increased their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Finally, JPMorgan Chase & Co. boosted their price target on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $280.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.